A multi-center study of high dose Aldesleukin (Proleukin®(HD IL-2) + Vemurafenib Zelboraf®) therapy in patients with BRAF$^{V600}$ mutation positive metastatic melanoma (proclivity 01)

Joseph Clark¹, Lawrence Flaherty², Marc Ernstoff³, Henry Koon⁴, Mohammed Milhem⁵, Gerald Militello⁶, Sanjiv Agarwala⁷, Brendan Curti⁸, Lee Cranmer⁹, Christopher D Lao¹⁰, Theodore F Logan¹¹, Jose Lutzky¹², Venkatesh Rudrapatna¹³, Gregory Daniels¹⁴, Bret Taback¹⁵, Sandra Aung¹⁶, James Lowder¹⁶*, David Lawson¹⁷

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

**Purpose**

To investigate whether the Vemurafenib-induced increased tumor antigen expression, T lymphocyte infiltration and tumor debulking improve the complete response rate induced by HD IL-2 in metastatic melanoma and if there is synergistic toxicity using the drugs in close approximation.

**Schema**

Adult patients with measurable metastatic or unresectable Stage III melanoma with no prior therapy and a BRAF$^{V600}$ mutation who are candidates for HD IL-2 are eligible for entry into the first cohort of 135 patients (figure 1). Six weeks of Vemurafenib therapy per package insert precedes

---

**Figure 1** Treatment of metastatic melanoma with HD IL-2 immunotherapy and targeted agent vemurafenib

¹Prometheus Laboratories, San Diego, CA, USA

Full list of author information is available at the end of the article

© 2014 Clark et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
up to 2 courses of HD IL-2. Vemurafenib is administered during the outpatient intervals between cycles of HD IL-2 and following completion. A second cohort of up to 50 similar patients already responding or stable with < 18 weeks of Vemurafenib therapy will also be accrued. The study was amended to permit prior anti-PD-1 therapy. The primary endpoint is Complete Response (CR) and near CR at 6 months of therapy.

Current status
Sixteen sites have enrolled patients. 41 patients have been enrolled to date, 27 in Cohort 1 and 14 in cohort 2. The Data Safety and Monitoring Board performed an initial safety analysis after the initial 8 patients which demonstrated no unexpected safety signal. An analysis of the effect of the combination on Progression Free Survival in both cohorts will be performed after the first 20% of patients in Cohort 1 have received at least one course of HD IL-2. The results of this analysis should be available at the time of the SITC meeting.

Authors' details
1Loyola University, Maywood, IL, USA. 2Karmanos Cancer Center, Detroit, MI, USA. 3Dartmouth University, Hanover, NH, USA. 4CWRU University Hospitals, Cleveland, Oh, USA. 5University of Iowa, Iowa City, IA, USA. 6Hematology/Oncology Clinic, USA. 7Saint Luke’s Cancer Center, Center Valley, PA, USA. 8Earle A. Chiles Research Institute, Portland, OR, USA. 9University of Arizona Cancer Center, Tucson, AZ, USA. 10University of Michigan, Ann Arbor, MI, USA. 11Indiana University, Indianapolis, IN, USA. 12University of Miami Medical Center, Miami, FL, USA. 13University of Minnesota, Minneapolis, MN, USA. 14Moore’s Cancer Center, La Jolla, CA, USA. 15Columbia University, New York, NY, USA. 16Prometheus Laboratories, San Diego, CA, USA. 17Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-P77